BiotechTube
Porsolt

Porsolt

Le Genest-Saint-Isle, France· Est.
porsolt.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Porsolt is a long-established, privately held preclinical CRO based in France, with over 35 years of experience serving pharmaceutical, biotech, and academic clients globally. It operates a large, purpose-built facility and offers comprehensive services spanning efficacy testing, safety pharmacology, pharmacokinetics, and predictive toxicology across numerous disease areas. The company differentiates itself through deep scientific expertise, a strong quality culture with over 20 years of continuous GLP compliance, and a flexible, client-centric approach. Its business model is entirely service-based, generating revenue from contracted research projects.

NeuroscienceCardiovascularDermatologyGastro-IntestinalInflammationOncologyObesity & Metabolic DisordersPainRespiratoryThrombosisUrogenital

Technology Platform

Integrated preclinical CRO platform offering in vitro, in ovo, ex vivo, and in vivo models across multiple species and disease areas. Capabilities include drug formulation, bioanalysis, clinical chemistry, hematology, immunoassays (ELISA, HTRF, flow cytometry), high-throughput cellular screening, and high-content histology. Supported by GLP compliance and AAALAC accreditation.

Funding History

1
UndisclosedUndisclosed

Opportunities

Growth is driven by increased outsourcing of R&D by pharmaceutical and biotech firms, particularly virtual and small companies lacking internal capacity.
The rise of complex therapeutic modalities (e.g., biologics, cell therapies) creates demand for specialized preclinical models and expertise, which Porsolt can provide through its continuous model development.

Risk Factors

Revenue is tied to client R&D budgets, which are cyclical and can be cut during economic downturns.
The preclinical CRO market is highly competitive with large global players.
Operational risk includes maintaining critical GLP compliance and AAALAC accreditation, as any loss would severely damage the business.

Competitive Landscape

Porsolt competes in the global preclinical CRO market against large, publicly traded players like Charles River Laboratories, Labcorp Drug Development, and Eurofins, as well as many niche and regional specialists. Its differentiation is based on deep scientific expertise, a collaborative 'Scientist to Scientist' model, flexibility, and a strong track record of quality and regulatory compliance over 35+ years.

More companies in Small Molecule Drugs →More companies in France →